Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2018 | Asciminib: overcoming TKI resistance and reducing toxicity in CML

Timothy Hughes • 12 Sep 2018
SOHO 2018
Chronic Myeloid Leukemia Leukemia Asciminib Imatinib Nilotinib

Asciminib, a new TKI, is being investigated in combination with imatinib in chronic phase chronic myeloid leukemia (CML) currently (NCT03578367). Timothy Hughes, MD, FRACP, FRCPA, of the Royal Adelaide Hospital, Adelaide, Australia, gives us an update on this exciting development here. Speaking from the 2018 Society of Hematologic Oncology (SOHO) Annual Meeting in Houston, TX, Prof. Hughes discusses the drug’s mechanism of action; as an allosteric inhibitor of BCR-ABL, it is less susceptible to the typical mutations driving TKI resistance and is more specific so has a lower toxicity. He also explores where in the treatment sequence asciminib would be best placed.

More from Timothy Hughes

1:08
Managing drug resistance in CP-CML with ponatinib and asciminib
Timothy Hughes • 9 Dec 2023
1:13
The ALLG CML13 ASCEND-CML study: high major molecular responses with asciminib treatment for CP-CML
Timothy Hughes • 9 Dec 2023
1:26
The efficacy of nilotinib treatment approaches in frontline CML
Timothy Hughes • 12 Jun 2022
2:20
Clinical trial updates in CML
Timothy Hughes • 12 Jun 2022

Related Videos

1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals